Comparison of Gadolinium-BOPTA and Ferucarbotran-Enhanced Three-Dimensional T1-Weighted Dynamic Liver Magnetic Resonance Imaging in the Same Patient
- 1 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 41 (3), 264-271
- https://doi.org/10.1097/01.rli.0000188359.72928.0f
Abstract
We sought to compare signal changes using Ferucarbotran and gadobenate dimeglumine (Gd-BOPTA) in dynamic 3D T1-weighted (T1w) GRE imaging of the liver. Thirty patients were prospectively included in the study. All patients underwent 2 high-field magnetic resonance (MR) examinations: first with Gd-BOPTA (Gd) and then after a mean interval of 4 days with ferucarbotran (Feru). Dynamic MRI was obtained with a 3D T1w GRE sequence (TR 6.33, TE 2.31, flip angle 20°). Contrast enhanced scans were assessed before intravenous injection of the contrast agent (precontrast), and postcontrast during the arterial phase (30 seconds), portal venous phase (60 seconds), and equilibrium phase (120 seconds). The signal intensities (SIs) of liver, spleen, aorta, and portal vein were defined by region of interest measurements. Signal intensity changes (SICs) and percentage signal intensity change (PSIC) were calculated using the formulas SIC = (SI pre − SI post)/SI pre and PSIC = SIC × 100%. Positive signal enhancement was observed after intravenous injection of Feru during all dynamic measurements, whereas the mean SI values were lower compared with Gd. During the portal venous phase the mean SI of Gd was up to a factor of 2.1 higher (portal vein). The widest difference of SIC was observed during the equilibrium phase for liver parenchyma (Gd, 1.03; Feru, 0.24). The dynamic signal courses were similar for liver, portal vein and aorta. Different signal courses were obtained for the spleen. Feru-enhanced T1w dynamic images demonstrated significant signal increases for liver, vessels, and spleen but overall lower signal intensities than Gd-BOPTA. The dynamic signal courses of ferucarbotran were similar to that of Gd-BOPTA during ll perfusion phases except in the spleen. Thus, it may be possible to detect typical enhancement pattern of focal liver lesions with Feru-enhanced dynamic T1w MRI.Keywords
This publication has 33 references indexed in Scilit:
- Influence of Human Serum Albumin on Longitudinal and Transverse Relaxation Rates (R1 and R2) of Magnetic Resonance Contrast AgentsInvestigative Radiology, 2006
- Magnetic Resonance Imaging With Hepatospecific Contrast Agents in Cirrhotic Rat LiversInvestigative Radiology, 2005
- Parallel acquisition techniques for accelerated volumetric interpolated breath‐hold examination magnetic resonance imaging of the upper abdomen: Assessment of image quality and lesion conspicuityJournal of Magnetic Resonance Imaging, 2005
- Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: Comparison with superparamagnetic iron oxide-enhanced MR imagingJournal of Magnetic Resonance Imaging, 2004
- Differenzierung von Leberläsionen mit SPIO-gestützten T1-w und T2-w MRT-Aufnahmen: Eine ROC-AnalyseRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2003
- Detektion von Leberläsionen mit der Gadolinium-verstärkten VIBE-Sequenz im Vergleich zur SPIO-verstärkten MRTRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2003
- Low-Dose Gadobenate Dimeglumine Versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the LiverInvestigative Radiology, 2003
- Gadobenate Dimeglumine (Gd-BOPTA)Investigative Radiology, 1998
- Magnetic Resonance Imaging of Focal Liver LesionsInvestigative Radiology, 1996
- Contrast‐enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxideJournal of Magnetic Resonance Imaging, 1994